J&J raises offer for Actelion to more than US$250 a share

LONDON: Johnson & Johnson’s talks to acquire Swiss drugmaker Actelion Ltd are progressing after the world’s biggest health-care products maker raised its offer, people with knowledge of the matter said.

Actelion rejected an initial proposal - valued at about US$246 a share (249 Swiss francs) - prompting J&J to raise the bid to more than US$250 per share, said one of the people, who asked not to be identified because the information is private.